Inflammation and autoimmunity as a central theme in neurodegenerative disorders: Fact or fiction?

Current Opinion in Investigational Drugs

Volumn 5, Issue 7, 2004, Pages 706-713

  Clarkson, Andrew N ^a   Rahman, Rosanna Ma ^a   Appleton, Ian ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Alzheimer's disease; Chemokines; Cytokines; Multiple sclerosis; Parkinson's disease; Stroke

Indexed keywords

CHEMOKINE; CYTOKINE;

AUTOIMMUNITY; BRAIN; CLASSIFICATION; COMPARATIVE STUDY; DEGENERATIVE DISEASE; HUMAN; IMMUNOLOGY; INFLAMMATION; REVIEW;

AUTOIMMUNITY; BRAIN; CHEMOKINES; CYTOKINES; HUMANS; INFLAMMATION; NEURODEGENERATIVE DISEASES;

EID: 5044250486     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Hortega DR: El 'ercer elemento' de los centros nerviosos. Poder fagocitario y movilidad de la microglia. Bol Soc Esp Biol Ano (1919) IX:154-166.
2. Hayes GM, Woodroofe MN, Cuzner ML: Microglia are the major cell type expressing MHC class II in human white matter. J Neurol Sci (1987) 80(1):25-37.
3. McGeer PL, McGeer EG: The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev (1995) 21(2):195-218.
4. Etminan M, Gill S, Samii A: Effects of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. Br Med J (2003) 327(7407):128-132.
5. Chen H, Zhang SM, Hernan MA, Schwarzchild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 60(8):1059-1064.
6. Rockson SG, Albers GW: Comparing guidelines: Anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol (2004) 43(6):929-935.
7. Doyle HA, Mamula MJ: Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol (2001) 22(8):443-449.
8. Rogers GE, Harding HW, Llewellyn-Smith IJ: The origin of citrulline-containing proteins in the hair follicle and the chemical nature of trichohyalin, an intracellular precursor. Biochim Biophys Acta (1977) 495(1):159-175.
9. van Boekel MAM, van Venrooij WJ: Modifications of arginines and their role in autoimmunity. Autoimmun Rev (2003) 2(2):57-62.
10. Moscarello MA, Pritzker L, Mastronardi FG, Wood DD: Peptidylarginine deiminase: A candidate factor in demyelinating disease. J Neurochem (2002) 81(2):335-343.
11. Moscarello MA, Wood DD, Ackerley C, Boulias C: Myelin in multiple sclerosis is developmentally immature. J Clin Invest (1994) 94(1):146-154.
12. Elkarim RA, Mustafa M, Kivisakk P, Link H, Bakhiet M: Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest (1998) 28(4):295-299.
13. Gribova IE, Gnedenko BB, Poleshchuk VV, Morozov SG: Level of interferon-γ, tumor necrosis factor α, and antibodies to them in blood serum from Parkinson disease patients. Biomed Khim (2003) 49(2):208-212.
14. Dicou E, Vermersch P, Penisson-Besnier I, Dubas F, Nerriere V: Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age. Autoimmunity (1997) 26(3):189- 194.
15. Sarchielli P, Galli F, Floridi A, Floridi A, Gallai V: Relevance of protein nitration in brain injury: A key pathophysiological mechanism in neurodegenerative, autoimmune, or inflammatory CNS diseases and stroke. Amino Acids (2003) 25(3-4):427-436.
16. Clarkson AN, Liu H, Pearson L, Kapoor M, Harrison JC, Sammut IA, Jackson DM, Appleton I: Neuroprotective effects of spermine following hypoxia-ischemia-induced brain damage: A mechanistic study. FASEB J (2004):doi:10.1096/fj.03-1203fje.
17. Sutherland BA, Shaw O, Clarkson AN, Srinivas R, Appleton I: Neuroprotective effects of (-)-epigallocatechin gallate in a rat model of hypoxia-ischaemia induced brain damage. Proc Aus Soc Clin Exp Pharmacol Toxicol (2003) 10:Abs 167.
18. Shaw O, Sutherland BA, Clarkson A, Srinivas R, Appleton I: Effects of the neuronal nitric oxide synthase inhibitor, ARL 17477, in the hypoxia-ischaemia model of neurodegeneration. Proc Aus Soc Clin Exp Pharmacol Toxicol (2003) 10:Abs 165.
19. Mandel S, Weinreb O, Amit T, Youdin MB: Cell signalling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3- gallate: Implications for neurodegenerative diseases. J Neurochem (2004) 88(6):1555-1569.
20. Allan SM, Rothwell NJ: Inflammation in central nervous system injury. Phil Trans R Soc Lond Biol (2003) 358(1438):1669-1677.
21. Ringheim GE Conant K: Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol (2004) 147(1-2):43-49.
22. Lafaille JJ: The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev (1998) 9:139-151.
23. 1-42. J Neuroimmunol (2002) 132(1-2):49-59.
24. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K: Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci (1991) 104(2):230-234.
25. Huang Y-M, Xiao B-G, Ozenci V, Kouwenhoven M, Teleshova N, Fredrikson S, Link H: Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol (1999) 99(1):82-90.
26. McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, Reid HH, Bernard CCA: Granulocyte macrophage colony-stimulating factor: A new putative therapeutic target in multiple sclerosis. J Exp Med (2001) 194(7):873-882.
27. Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O: Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: A correlation with clinical activity. Immunopharmacol Immunotoxicol (1998) 20(3):373-382.
28. Issazadeh S, Ljungdahl A, Hojeberg B, Mustafa M, Olsson T: Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β. J Neuroimmunol (1995) 61(2):205-212.
29. 1 J Immunol (1991) 146(9):3012-3017.
30. Leonardi A, Penco S, Gramigni C, Bason C, Ribizzi G, Gazzola P, Mancardi GL, Bianchi-Scarra G, Abbruzzese M, Garre C: Granulocyte-macrophage colony-stimulating factor activity in cerebrospinal fluid. Acta Neurol Scand (1999) 100(4):272-277.
31. Szczepanik A-M, Funes S, Petko W, Ringheim GE: IL-4, IL-10 and IL-13 modulate Aβ(1-42)-induced cytokine and chemokine production in primary microglia and a human monocyte cell line. J Neuroimmunol (2001) 113(1):49-62.
32. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B: TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J (1999) 13(1):63-68.
33. Tarkowski E, Liljeroth A-M, Minthon L, Tarkowski A, Wallin A, Blennow K: Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull (2003) 61(3):255-260.
34. Abbas N, Bednar I, Mix E, Marie S, Paterson D, Ljungberg A, Morris C, Winblad B, Nordberg A, Zhu J: Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol (2002) 126(1-2):50- 57.
35. Bongioanni P, Boccardi B, Borgna M, Castagna M, Mondino C: T-cell interferon γ binding in patients with dementia of the Alzheimer type. Arch Neurol (1997) 54(4):457-462.
36. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P: Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer's disease and vascular dementia. Neurobiol Aging (2002) 23(2):237-243.
37. Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A: Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand (2001) 103(3):166-174.
38. Murphy GM Jr, Yang L, Cordell B: Macrophage colony-stimulating factor augments β-amyloid-induced interleukin-1, interleukin-6 and nitric oxide production by microglial cells. J Biol Chem (1998) 273(33):20967-20971.
39. Wersinger C, Sidhu A: Inflammation and Parkinson's disease. Curr Drug Targets - Inflamm Allergy (2002) 1(3):221-242.
40. Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M: IL-1β, IL-2, IL-6 and TNF-α production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother (1999) 53(3):141-145.
41. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T: Interleukin-1 β, interleukin-6, epidermal growth factor and transforming growth factor-β are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 180(2):147-150.
42. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1 β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 202(1-2):17-20.
43. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-α (TNF-α) increase both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 165(1-2):208-210.
44. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T: Interleukin (IL)-1β, IL-2, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett (1996) 211(1):13-16.
45. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 22(5):1763-1771.
46. Hill JK, Gunion-Rinker L, Kulhanek D, Lessov N, Kim S, Clark WM, Dixon MP, Nishi R, Stenzel-Poore MP, Eckenstein FP: Temporal modulation of cytokine expression following focal cerebral ischemia in mice. Brain Res (1999) 820(1-2):45-54.
47. Gregersen R, Lambertsen K, Finsen B: Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab (2000) 20(1):53-65.
48. Legos JJ, Whitmore RG, Erhardt JA, Parsons AA, Tuma RF, Barone FC: Quantitative changes in interleukin proteins following focal stroke in the rat. Neurosci Lett (2000) 282(3):189-192.
49. Clark WM, Rinker LG, Lessov NS, Hazel K, Eckenstein F: Time course of IL-6 expression in experimental CNS ischemia. Neurol Res (1999) 21(3):287-292.
50. Vila N, Reverter JC, Yague J, Chamorro A: Interaction between interleukin-6 and the natural anticoagulant system in acute stroke. J Interferon Cytokine Res (2000) 20(3):325-329.
51. Kouwenhoven M, Carlström C, Özenci V, Link H: Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol (2001) 21(5):365-375.
52. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, Tarkowski A: Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol (1997) 110(3):492-499.
53. Yin L, Ohtaki H, Nakamachi T, Dohi K, Iwai Y, Funahashi H, Makino R, Shioda S: Expression of tumor necrosis factor α (TNFα) following transient cerebral ischemia. Acta Neurochir Suppl (2003) 86:93-96.
54. Pelidou S-H, Kostulas N, Matusevicius D, Kivisakk P, Kostulas V, Link H: High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol (1999) 6(4):437-442.
55. Kim HM, Shin HY, Jeong HJ, An HJ, Kim NS, Chae HJ, Kim HR, Song HJ, Kim KY, Baek SH, Cho KH et al: Reduced IL-2 but elevated IL-4, IL-6 and IgE serum levels in patients with cerebral infarction during the acute stage. J Mol Neurosci (2000) 14(3):191-196.
56. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V: Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci (2001) 22(4):289-296.
57. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G, Ongini E: Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur J Neurosci (2000) 12(7):2265-2272.
58. Spera PA, Ellison JA, Feuerstein GZ, Barone FC: IL-10 reduces rat brain injury following focal stroke. Neurosci Lett (1998) 251(3):189-192.
59. van Exel E, Gussekloo J, de Craen AJM, Bootsma-van der Wiel A, Frolich M, Westendorp RGJ: Inflammation and stroke: The Leiden 85-Plus Study. Stroke (2002) 33(4):1135-1138.
60. Buisson A, Lesne S, Docagne F, Ali C, Nicole O, MacKenzie ET, Vivien D: Transforming growth factor-β and ischemic brain injury. Cell Mol Neurobiol (2003) 23(4-5):539-550.
61. Krupinski J, Kumar P, Kumar S, Kaluza J: Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans. Stroke (1996) 27(5):852-857.
62. Appleton I: Wound healing: Future directions. IDrugs (2003) 6(11):1067-1072.
63. Lehrmann E, Kiefer R, Christensen T, Toyka KV, Zimmer J, Diemer NH, Hartung H-P, Finsen B: Microglia and macrophages are major sources of locally produced transforming growth factor-β1 after transient middle cerebral artery occlusion in rats. Glia (1998) 24(4):437-448.
64. Gross CE, Bednar MM, Howard DB, Sporn MB: Transforming growth factor-β1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke (1993) 24(4):558-562.
65. Ruocco A, Nicole O, Docagne F, Ali C, Chazalviel L, Komesli S, Yablonsky F, Roussel S, MacKenzie ET, Vivien D, Buisson A: A transforming growth factor-β antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J Cereb Blood Flow Metab (1999) 19(12):1345-1353.
66. Feuerstein GZ, Wang X: Inflammation and stroke: Benefits without harm? Arch Neurol (2001) 58(4):672-674.
67. Whitaker JN: The potential for harm or benefit from inflammatory processes in stroke. Arch Neurol (2001) 58(4):674.
68. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Wtte M, Lorton D et al: Amyloid-β induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med (1998) 4(7):480-489.
69. Nagatsu T, Mogi M, Ichinose H, Togari A: Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl (2000) 60:277-290.
70. Link J, Soderstorm M, Olsson T, Hojeberg B, Ljungdahl A, Link H: Increased transforming growth factor-β, interleukin-4, and interferonγ in multiple sclerosis. Ann Neurol (1994) 36(3):379-386.
71. Matusevicius D, Kivisakk P, Navikas V, Soderstrom M, Fredrikson S, Link H: Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. Scand J Immunol (1998)47(6):582-590.
72. Baker D, O'Neill JK, Turk JL: Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis. Cell Immunol (1991) 134(2):505-510.
73. Kennedy MK, Torrance DS, Picha KS, Mohler KM: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol (1992) 149(7):2496-2505.
74. Asensio VC, Campbell IL: Chemokines in the CNS: Plurifunctional mediators in diverse states. Trends Neurosci (1999) 22(11):504-512.
75. Ransohoff RM, Bacon KB: Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs (2000) 9(5):1079-1097.
76. Bajetto A, Bonavia R, Barbero S, Schettini G: Characterization of chemokines and their receptors in the central nervous system: Physiopathological implications. J Neurochem (2002) 82(6):1311-1329.
77. Huang D, Han Y, Rani MR, Glabinski A, Trebst C, Sorensen T, Tani M, Wang J, Chien P, O'Bryan S, Bielecki B et al: Chemokines and chemokine receptors in inflammation of the nervous system: Manifold roles and exquisite regulation. Immunol Rev (2000) 177:52-67.
78. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol (1998) 84(2):238-249.
79. Miyagishi R, Kikuchi S, Takayama C, Inoue Y, Tashiro K: Identification of cell types producing RANTES, MIP-1α and MIP-1β in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol (1997) 77(1):17-26.
80. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest (1999) 103(6):807-815.
81. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K: Macrophage inflammatory protein-1α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci (1995) 129(2):223-227.
82. Schroter M, Jander S, Witte OW, Stoll G: Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol (1994) 55(2):195-203.
83. Gourmala NG, Buttini M, Limonta S, Sauter A, Boddeke HW: Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: Effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol (1997) 74(1-2):35-44.
84. Bona E, Andersson A-L, Blomgren K, Gillard E, Puka-Sundvall M, Gustafson K, Hagberg H: Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats. Pediatr Res (1999) 45(4 Pt 1):500-509.
85. Wang X, Ellison JA, Siren AL, Lysko PG, Yue TL, Barone FC, Shatzman A, Feuerstein GZ: Prolonged expression of interferon-inducible protein-10 in ischemic cortex after permanent occlusion of the middle cerebral artery in rat. J Neurochem (1998) 71(3):1194-1204.
86. Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SC, Menon DK: Neuroprotection in ischemia-reperfusion injury: An antiinflammatory approach using a novel broad-spectrum chemokine inhibitor. J Cereb Blood Flow Metab (2001) 21(6):683-689.
87. Green AR, Ashwood T, Odergren T, Jackson DM: Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther (2003) 100(3):195-214.
88. Green AR: Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin Exp Pharmacol Physiol (2002) 29(11):1030-1034.
89. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF: MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study. J Neuroimmunol (1998) 86(1):20-29.
90. Karpus WJ, Ransohoff RM: Chemokine regulation of experimental autoimmune encephalomyelitis: Temporal and spatial expression patterns govern disease pathogenesis. J Immunol (1998) 161(6):2667-2671.
91. Luo Y, Fischer FR, Hancock WW, Dorf ME: Macrophage inflammatory protein-2 and KC induce chemokine production by mouse astrocytes. J Immunol (2000) 165(7):4015-4023.
92. Godiska R, Chantry D, Dietsch GN, Gray PW: Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol (1995) 58(2):167-176.
93. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T: Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci (1997) 51(3):135-138.
94. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P: Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol (2003) 53(4):547-548.
95. Johnstone M, Gearing AJ, Miller KM: A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol (1999) 93(1-2):182-193.
96. Nishimura M, Kuno S, Mizuta I, Ohta M, Maruyama H, Kaji R, Kawakami H: Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease. Mov Disord (2003) 18(8):953-955.
97. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT: Immunohistochemical study of the β-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol (1998) 153(1):31-37.
98. Wang X, Li X, Yaish-Ohad S, Sarau HM, Barone FC, Feuerstein GZ: Molecular cloning and expression of the rat monocyte chemotactic protein-3 gene: A possible role in stroke. Brain Res Mol Brain Res (1999) 71(2):304-312.
99. Balashov KE, Rottman JB, Weiner HL, Hancock WW: CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA (1999) 96(12):6873-6878.
100. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT: Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: In vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol (2000) 108(1-2):227-235.